Does a Statistically Significant Survival Benefit of Erlotinib Plus Gemcitabine for Advanced Pancreatic Cancer Translate Into Clinical Significance and Value?
- 1 October 2007
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (28), 4506-4507
- https://doi.org/10.1200/jco.2007.13.0401
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Burden of Pancreatic Cancer and Disease Progression: Economic Analysis in the USOncology, 2006
- Utilities For Prostate Cancer Health States in Men Aged 60 and OlderMedical Care, 2005
- Pancreatic cancerThe Lancet, 2004
- Systematic Overview of Cost-Utility Assessments in OncologyJournal of Clinical Oncology, 2000